

Table 2. Risedronate (Actonel) for postmenopausal osteoporosis

Study	Regimens	Treatment Duration	N	Endpoints	Results
Reginster et al ⁴ (treatment)	Risedronate: 2.5 mg/d, 5 mg/d, or placebo	3 years	1,226	Vertebral fractures	5 mg/d group had significantly fewer new vertebral fractures than the control group after three years, 53 vs. 89 (P < 0.001). However, there was not a significant difference in the number of osteoporosis-related nonvertebral fractures between the 5 mg/d group and the control group, 36 vs. 51.
Harris et al ³ (treatment)	Risedronate: 2.5 mg/d, 5 mg/d, or placebo	3 years	2,458	Vertebral and nonvertebral fractures	5 mg/d decreased cumulative incidence of new vertebral fractures by 41% (P < 0.003) and decreased incidence of nonvertebral fractures by 39% (P < 0.02) compared to placebo.